Loading…

The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix

Adenocarcinoma in situ (ACIS) and adenocarcinoma (AdCA) of the cervix are frequently missed in population‐based screening programmes. Adding high‐risk HPV (hrHPV) testing to cervical cancer screening might improve the detection rate of ACIS and AdCA. Since the exact proportion of AdCAs of the cervix...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pathology 2003-12, Vol.201 (4), p.535-543
Main Authors: Zielinski, G Denise, Snijders, Peter JF, Rozendaal, Lawrence, Daalmeijer, Nathalie Fransen, Risse, Elle KJ, Voorhorst, Feja J, Jiwa, N Medi, van der Linden, Hans C, de Schipper, Frits A, Runsink, Arnold P, Meijer, Chris JLM
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 543
container_issue 4
container_start_page 535
container_title The Journal of pathology
container_volume 201
creator Zielinski, G Denise
Snijders, Peter JF
Rozendaal, Lawrence
Daalmeijer, Nathalie Fransen
Risse, Elle KJ
Voorhorst, Feja J
Jiwa, N Medi
van der Linden, Hans C
de Schipper, Frits A
Runsink, Arnold P
Meijer, Chris JLM
description Adenocarcinoma in situ (ACIS) and adenocarcinoma (AdCA) of the cervix are frequently missed in population‐based screening programmes. Adding high‐risk HPV (hrHPV) testing to cervical cancer screening might improve the detection rate of ACIS and AdCA. Since the exact proportion of AdCAs of the cervix that can be attributed to hrHPV infection is still a matter of debate, a comprehensive study was performed of hrHPV presence in ACIS and AdCA of the cervix. Archival formalin‐fixed specimens of indisputable ACIS (n = 65) and AdCA (n = 77) of the cervix were tested for hrHPV DNA by GP5+/6+ PCR‐enzyme immunoassay (EIA) and type‐specific E7 PCR for 14 hrHPV types. Further immunostaining for p16INK4A and p53 was performed to assess alternative pathways of carcinogenesis potentially unrelated to HPV. hrHPV DNA was found in all (100%) ACISs and 72 (94%) cervical AdCAs, whereas none of 20 endometrial AdCAs scored hrHPV‐positive. HPV 18 was most prevalent and found as single or multiple infection in 68% of ACISs and 55% of cervical AdCAs. Diffuse immunostaining for p16INK4a, a potential marker of hrHPV E7 function, was significantly more frequent in hrHPV‐positive cervical AdCAs (19/20; 95%) than in those without hrHPV (1/5; 20%; p < 0.001). Immunostaining for p53, pointing to stabilized wild‐type or mutant p53 protein, was significantly more frequent in hrHPV cervical AdCAs negative for hrHPV (p = 0.01). No difference in p16INK4a and p53 immunostaining was found between hrHPV‐negative cervical AdCAs and endometrial AdCAs. Hence, only a minority of cervical AdCAs displayed absence of HPV DNA and immunostaining profiles suggestive of an aetiology independent of HPV. Since all ACISs and nearly all cervical AdCAs were hrHPV‐positive, the incorporation of hrHPV testing in cervical cancer screening programmes is likely to decrease markedly the incidence of cervical AdCA. Copyright © 2003 John Wiley & Sons, Ltd.
doi_str_mv 10.1002/path.1480
format article
fullrecord <record><control><sourceid>istex_pubme</sourceid><recordid>TN_cdi_pubmed_primary_14648656</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_WNG_XPL48R80_B</sourcerecordid><originalsourceid>FETCH-LOGICAL-i1620-fa5fbb5383d5a0014016d66eeaa7a2a9081a3a4f0eba42b177fb3f637a1a8e4e3</originalsourceid><addsrcrecordid>eNpdkc1u1DAUhS0EokNhwQsgb1imtWPHSZalgk7FqIzQ8LOzbpzrxnTiRHamnT4ib4XDFCp1ZcvnO-de-RDylrMTzlh-OsLUnXBZsWdkwVmtsrqq1XOySFqeCcnLI_Iqxl-MsbouipfkiEslK1WoBfm96ZCOASN6g3SwtHPXXRZcvKHL9Xdqhr5xHlt656aOxhGNs87QsRAUfEtHri6vPkuguJ8zohs8TctMGHyk4-D8FOk0PMmE9JaG9uA8NbCLMLlbpHCNfqJ2CBRa9IOBYJwfeqCJim7a_Z33RErrzkkGw63bvyYvLGwjvnk4j8m3Tx8358ts9eXi8vxslTmucpZZKGzTFKISbQGMccm4apVCBCghh5pVHARIy7ABmTe8LG0jrBIlcKhQojgm7w65467psdVjcD2Ee_3vTxPw_gGAaGBrA3jj4iNXCCHziiXu9MDduS3eP-pMz6XquVQ9l6rXZ5vlfEmO7OBwccL9fweEG61KURb6x9WF_rleyeprsn0QfwCU56Zh</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix</title><source>Wiley</source><creator>Zielinski, G Denise ; Snijders, Peter JF ; Rozendaal, Lawrence ; Daalmeijer, Nathalie Fransen ; Risse, Elle KJ ; Voorhorst, Feja J ; Jiwa, N Medi ; van der Linden, Hans C ; de Schipper, Frits A ; Runsink, Arnold P ; Meijer, Chris JLM</creator><creatorcontrib>Zielinski, G Denise ; Snijders, Peter JF ; Rozendaal, Lawrence ; Daalmeijer, Nathalie Fransen ; Risse, Elle KJ ; Voorhorst, Feja J ; Jiwa, N Medi ; van der Linden, Hans C ; de Schipper, Frits A ; Runsink, Arnold P ; Meijer, Chris JLM</creatorcontrib><description>Adenocarcinoma in situ (ACIS) and adenocarcinoma (AdCA) of the cervix are frequently missed in population‐based screening programmes. Adding high‐risk HPV (hrHPV) testing to cervical cancer screening might improve the detection rate of ACIS and AdCA. Since the exact proportion of AdCAs of the cervix that can be attributed to hrHPV infection is still a matter of debate, a comprehensive study was performed of hrHPV presence in ACIS and AdCA of the cervix. Archival formalin‐fixed specimens of indisputable ACIS (n = 65) and AdCA (n = 77) of the cervix were tested for hrHPV DNA by GP5+/6+ PCR‐enzyme immunoassay (EIA) and type‐specific E7 PCR for 14 hrHPV types. Further immunostaining for p16INK4A and p53 was performed to assess alternative pathways of carcinogenesis potentially unrelated to HPV. hrHPV DNA was found in all (100%) ACISs and 72 (94%) cervical AdCAs, whereas none of 20 endometrial AdCAs scored hrHPV‐positive. HPV 18 was most prevalent and found as single or multiple infection in 68% of ACISs and 55% of cervical AdCAs. Diffuse immunostaining for p16INK4a, a potential marker of hrHPV E7 function, was significantly more frequent in hrHPV‐positive cervical AdCAs (19/20; 95%) than in those without hrHPV (1/5; 20%; p &lt; 0.001). Immunostaining for p53, pointing to stabilized wild‐type or mutant p53 protein, was significantly more frequent in hrHPV cervical AdCAs negative for hrHPV (p = 0.01). No difference in p16INK4a and p53 immunostaining was found between hrHPV‐negative cervical AdCAs and endometrial AdCAs. Hence, only a minority of cervical AdCAs displayed absence of HPV DNA and immunostaining profiles suggestive of an aetiology independent of HPV. Since all ACISs and nearly all cervical AdCAs were hrHPV‐positive, the incorporation of hrHPV testing in cervical cancer screening programmes is likely to decrease markedly the incidence of cervical AdCA. Copyright © 2003 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 0022-3417</identifier><identifier>EISSN: 1096-9896</identifier><identifier>DOI: 10.1002/path.1480</identifier><identifier>PMID: 14648656</identifier><identifier>CODEN: JPTLAS</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Adenocarcinoma - etiology ; Adenocarcinoma - genetics ; Adenocarcinoma - pathology ; Adult ; Biological and medical sciences ; Carcinoma in Situ - etiology ; Carcinoma in Situ - genetics ; Carcinoma in Situ - pathology ; cervical adenocarcinoma ; cervical adenocarcinoma in situ ; DNA, Neoplasm - analysis ; DNA, Viral - analysis ; endometrial adenocarcinoma ; Endometrial Neoplasms - etiology ; Endometrial Neoplasms - genetics ; Female ; Female genital diseases ; Gene Expression Regulation, Neoplastic - genetics ; Genes, p16 ; Genes, p53 - genetics ; Gynecology. Andrology. Obstetrics ; HPV ; Humans ; Immunohistochemistry - methods ; Medical sciences ; Middle Aged ; Non tumoral diseases ; p16INK4a ; p53 ; Papillomaviridae - genetics ; Papillomavirus Infections - complications ; Papillomavirus Infections - genetics ; Papillomavirus Infections - pathology ; Polymerase Chain Reaction - methods ; Risk Factors ; Uterine Cervical Neoplasms - etiology ; Uterine Cervical Neoplasms - genetics ; Uterine Cervical Neoplasms - pathology</subject><ispartof>The Journal of pathology, 2003-12, Vol.201 (4), p.535-543</ispartof><rights>Copyright © 2003 John Wiley &amp; Sons, Ltd.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2003 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15334280$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14648656$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zielinski, G Denise</creatorcontrib><creatorcontrib>Snijders, Peter JF</creatorcontrib><creatorcontrib>Rozendaal, Lawrence</creatorcontrib><creatorcontrib>Daalmeijer, Nathalie Fransen</creatorcontrib><creatorcontrib>Risse, Elle KJ</creatorcontrib><creatorcontrib>Voorhorst, Feja J</creatorcontrib><creatorcontrib>Jiwa, N Medi</creatorcontrib><creatorcontrib>van der Linden, Hans C</creatorcontrib><creatorcontrib>de Schipper, Frits A</creatorcontrib><creatorcontrib>Runsink, Arnold P</creatorcontrib><creatorcontrib>Meijer, Chris JLM</creatorcontrib><title>The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix</title><title>The Journal of pathology</title><addtitle>J. Pathol</addtitle><description>Adenocarcinoma in situ (ACIS) and adenocarcinoma (AdCA) of the cervix are frequently missed in population‐based screening programmes. Adding high‐risk HPV (hrHPV) testing to cervical cancer screening might improve the detection rate of ACIS and AdCA. Since the exact proportion of AdCAs of the cervix that can be attributed to hrHPV infection is still a matter of debate, a comprehensive study was performed of hrHPV presence in ACIS and AdCA of the cervix. Archival formalin‐fixed specimens of indisputable ACIS (n = 65) and AdCA (n = 77) of the cervix were tested for hrHPV DNA by GP5+/6+ PCR‐enzyme immunoassay (EIA) and type‐specific E7 PCR for 14 hrHPV types. Further immunostaining for p16INK4A and p53 was performed to assess alternative pathways of carcinogenesis potentially unrelated to HPV. hrHPV DNA was found in all (100%) ACISs and 72 (94%) cervical AdCAs, whereas none of 20 endometrial AdCAs scored hrHPV‐positive. HPV 18 was most prevalent and found as single or multiple infection in 68% of ACISs and 55% of cervical AdCAs. Diffuse immunostaining for p16INK4a, a potential marker of hrHPV E7 function, was significantly more frequent in hrHPV‐positive cervical AdCAs (19/20; 95%) than in those without hrHPV (1/5; 20%; p &lt; 0.001). Immunostaining for p53, pointing to stabilized wild‐type or mutant p53 protein, was significantly more frequent in hrHPV cervical AdCAs negative for hrHPV (p = 0.01). No difference in p16INK4a and p53 immunostaining was found between hrHPV‐negative cervical AdCAs and endometrial AdCAs. Hence, only a minority of cervical AdCAs displayed absence of HPV DNA and immunostaining profiles suggestive of an aetiology independent of HPV. Since all ACISs and nearly all cervical AdCAs were hrHPV‐positive, the incorporation of hrHPV testing in cervical cancer screening programmes is likely to decrease markedly the incidence of cervical AdCA. Copyright © 2003 John Wiley &amp; Sons, Ltd.</description><subject>Adenocarcinoma - etiology</subject><subject>Adenocarcinoma - genetics</subject><subject>Adenocarcinoma - pathology</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Carcinoma in Situ - etiology</subject><subject>Carcinoma in Situ - genetics</subject><subject>Carcinoma in Situ - pathology</subject><subject>cervical adenocarcinoma</subject><subject>cervical adenocarcinoma in situ</subject><subject>DNA, Neoplasm - analysis</subject><subject>DNA, Viral - analysis</subject><subject>endometrial adenocarcinoma</subject><subject>Endometrial Neoplasms - etiology</subject><subject>Endometrial Neoplasms - genetics</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gene Expression Regulation, Neoplastic - genetics</subject><subject>Genes, p16</subject><subject>Genes, p53 - genetics</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>HPV</subject><subject>Humans</subject><subject>Immunohistochemistry - methods</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Non tumoral diseases</subject><subject>p16INK4a</subject><subject>p53</subject><subject>Papillomaviridae - genetics</subject><subject>Papillomavirus Infections - complications</subject><subject>Papillomavirus Infections - genetics</subject><subject>Papillomavirus Infections - pathology</subject><subject>Polymerase Chain Reaction - methods</subject><subject>Risk Factors</subject><subject>Uterine Cervical Neoplasms - etiology</subject><subject>Uterine Cervical Neoplasms - genetics</subject><subject>Uterine Cervical Neoplasms - pathology</subject><issn>0022-3417</issn><issn>1096-9896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpdkc1u1DAUhS0EokNhwQsgb1imtWPHSZalgk7FqIzQ8LOzbpzrxnTiRHamnT4ib4XDFCp1ZcvnO-de-RDylrMTzlh-OsLUnXBZsWdkwVmtsrqq1XOySFqeCcnLI_Iqxl-MsbouipfkiEslK1WoBfm96ZCOASN6g3SwtHPXXRZcvKHL9Xdqhr5xHlt656aOxhGNs87QsRAUfEtHri6vPkuguJ8zohs8TctMGHyk4-D8FOk0PMmE9JaG9uA8NbCLMLlbpHCNfqJ2CBRa9IOBYJwfeqCJim7a_Z33RErrzkkGw63bvyYvLGwjvnk4j8m3Tx8358ts9eXi8vxslTmucpZZKGzTFKISbQGMccm4apVCBCghh5pVHARIy7ABmTe8LG0jrBIlcKhQojgm7w65467psdVjcD2Ee_3vTxPw_gGAaGBrA3jj4iNXCCHziiXu9MDduS3eP-pMz6XquVQ9l6rXZ5vlfEmO7OBwccL9fweEG61KURb6x9WF_rleyeprsn0QfwCU56Zh</recordid><startdate>200312</startdate><enddate>200312</enddate><creator>Zielinski, G Denise</creator><creator>Snijders, Peter JF</creator><creator>Rozendaal, Lawrence</creator><creator>Daalmeijer, Nathalie Fransen</creator><creator>Risse, Elle KJ</creator><creator>Voorhorst, Feja J</creator><creator>Jiwa, N Medi</creator><creator>van der Linden, Hans C</creator><creator>de Schipper, Frits A</creator><creator>Runsink, Arnold P</creator><creator>Meijer, Chris JLM</creator><general>John Wiley &amp; Sons, Ltd</general><general>Wiley</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200312</creationdate><title>The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix</title><author>Zielinski, G Denise ; Snijders, Peter JF ; Rozendaal, Lawrence ; Daalmeijer, Nathalie Fransen ; Risse, Elle KJ ; Voorhorst, Feja J ; Jiwa, N Medi ; van der Linden, Hans C ; de Schipper, Frits A ; Runsink, Arnold P ; Meijer, Chris JLM</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i1620-fa5fbb5383d5a0014016d66eeaa7a2a9081a3a4f0eba42b177fb3f637a1a8e4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adenocarcinoma - etiology</topic><topic>Adenocarcinoma - genetics</topic><topic>Adenocarcinoma - pathology</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Carcinoma in Situ - etiology</topic><topic>Carcinoma in Situ - genetics</topic><topic>Carcinoma in Situ - pathology</topic><topic>cervical adenocarcinoma</topic><topic>cervical adenocarcinoma in situ</topic><topic>DNA, Neoplasm - analysis</topic><topic>DNA, Viral - analysis</topic><topic>endometrial adenocarcinoma</topic><topic>Endometrial Neoplasms - etiology</topic><topic>Endometrial Neoplasms - genetics</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gene Expression Regulation, Neoplastic - genetics</topic><topic>Genes, p16</topic><topic>Genes, p53 - genetics</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>HPV</topic><topic>Humans</topic><topic>Immunohistochemistry - methods</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Non tumoral diseases</topic><topic>p16INK4a</topic><topic>p53</topic><topic>Papillomaviridae - genetics</topic><topic>Papillomavirus Infections - complications</topic><topic>Papillomavirus Infections - genetics</topic><topic>Papillomavirus Infections - pathology</topic><topic>Polymerase Chain Reaction - methods</topic><topic>Risk Factors</topic><topic>Uterine Cervical Neoplasms - etiology</topic><topic>Uterine Cervical Neoplasms - genetics</topic><topic>Uterine Cervical Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zielinski, G Denise</creatorcontrib><creatorcontrib>Snijders, Peter JF</creatorcontrib><creatorcontrib>Rozendaal, Lawrence</creatorcontrib><creatorcontrib>Daalmeijer, Nathalie Fransen</creatorcontrib><creatorcontrib>Risse, Elle KJ</creatorcontrib><creatorcontrib>Voorhorst, Feja J</creatorcontrib><creatorcontrib>Jiwa, N Medi</creatorcontrib><creatorcontrib>van der Linden, Hans C</creatorcontrib><creatorcontrib>de Schipper, Frits A</creatorcontrib><creatorcontrib>Runsink, Arnold P</creatorcontrib><creatorcontrib>Meijer, Chris JLM</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>The Journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zielinski, G Denise</au><au>Snijders, Peter JF</au><au>Rozendaal, Lawrence</au><au>Daalmeijer, Nathalie Fransen</au><au>Risse, Elle KJ</au><au>Voorhorst, Feja J</au><au>Jiwa, N Medi</au><au>van der Linden, Hans C</au><au>de Schipper, Frits A</au><au>Runsink, Arnold P</au><au>Meijer, Chris JLM</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix</atitle><jtitle>The Journal of pathology</jtitle><addtitle>J. Pathol</addtitle><date>2003-12</date><risdate>2003</risdate><volume>201</volume><issue>4</issue><spage>535</spage><epage>543</epage><pages>535-543</pages><issn>0022-3417</issn><eissn>1096-9896</eissn><coden>JPTLAS</coden><abstract>Adenocarcinoma in situ (ACIS) and adenocarcinoma (AdCA) of the cervix are frequently missed in population‐based screening programmes. Adding high‐risk HPV (hrHPV) testing to cervical cancer screening might improve the detection rate of ACIS and AdCA. Since the exact proportion of AdCAs of the cervix that can be attributed to hrHPV infection is still a matter of debate, a comprehensive study was performed of hrHPV presence in ACIS and AdCA of the cervix. Archival formalin‐fixed specimens of indisputable ACIS (n = 65) and AdCA (n = 77) of the cervix were tested for hrHPV DNA by GP5+/6+ PCR‐enzyme immunoassay (EIA) and type‐specific E7 PCR for 14 hrHPV types. Further immunostaining for p16INK4A and p53 was performed to assess alternative pathways of carcinogenesis potentially unrelated to HPV. hrHPV DNA was found in all (100%) ACISs and 72 (94%) cervical AdCAs, whereas none of 20 endometrial AdCAs scored hrHPV‐positive. HPV 18 was most prevalent and found as single or multiple infection in 68% of ACISs and 55% of cervical AdCAs. Diffuse immunostaining for p16INK4a, a potential marker of hrHPV E7 function, was significantly more frequent in hrHPV‐positive cervical AdCAs (19/20; 95%) than in those without hrHPV (1/5; 20%; p &lt; 0.001). Immunostaining for p53, pointing to stabilized wild‐type or mutant p53 protein, was significantly more frequent in hrHPV cervical AdCAs negative for hrHPV (p = 0.01). No difference in p16INK4a and p53 immunostaining was found between hrHPV‐negative cervical AdCAs and endometrial AdCAs. Hence, only a minority of cervical AdCAs displayed absence of HPV DNA and immunostaining profiles suggestive of an aetiology independent of HPV. Since all ACISs and nearly all cervical AdCAs were hrHPV‐positive, the incorporation of hrHPV testing in cervical cancer screening programmes is likely to decrease markedly the incidence of cervical AdCA. Copyright © 2003 John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>14648656</pmid><doi>10.1002/path.1480</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3417
ispartof The Journal of pathology, 2003-12, Vol.201 (4), p.535-543
issn 0022-3417
1096-9896
language eng
recordid cdi_pubmed_primary_14648656
source Wiley
subjects Adenocarcinoma - etiology
Adenocarcinoma - genetics
Adenocarcinoma - pathology
Adult
Biological and medical sciences
Carcinoma in Situ - etiology
Carcinoma in Situ - genetics
Carcinoma in Situ - pathology
cervical adenocarcinoma
cervical adenocarcinoma in situ
DNA, Neoplasm - analysis
DNA, Viral - analysis
endometrial adenocarcinoma
Endometrial Neoplasms - etiology
Endometrial Neoplasms - genetics
Female
Female genital diseases
Gene Expression Regulation, Neoplastic - genetics
Genes, p16
Genes, p53 - genetics
Gynecology. Andrology. Obstetrics
HPV
Humans
Immunohistochemistry - methods
Medical sciences
Middle Aged
Non tumoral diseases
p16INK4a
p53
Papillomaviridae - genetics
Papillomavirus Infections - complications
Papillomavirus Infections - genetics
Papillomavirus Infections - pathology
Polymerase Chain Reaction - methods
Risk Factors
Uterine Cervical Neoplasms - etiology
Uterine Cervical Neoplasms - genetics
Uterine Cervical Neoplasms - pathology
title The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T15%3A03%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20presence%20of%20high-risk%20HPV%20combined%20with%20specific%20p53%20and%20p16INK4a%20expression%20patterns%20points%20to%20high-risk%20HPV%20as%20the%20main%20causative%20agent%20for%20adenocarcinoma%20in%20situ%20and%20adenocarcinoma%20of%20the%20cervix&rft.jtitle=The%20Journal%20of%20pathology&rft.au=Zielinski,%20G%20Denise&rft.date=2003-12&rft.volume=201&rft.issue=4&rft.spage=535&rft.epage=543&rft.pages=535-543&rft.issn=0022-3417&rft.eissn=1096-9896&rft.coden=JPTLAS&rft_id=info:doi/10.1002/path.1480&rft_dat=%3Cistex_pubme%3Eark_67375_WNG_XPL48R80_B%3C/istex_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-i1620-fa5fbb5383d5a0014016d66eeaa7a2a9081a3a4f0eba42b177fb3f637a1a8e4e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/14648656&rfr_iscdi=true